Rxsight, INC Form 4 insider transactions

RxSight's CEO, Ronald Kurtz, exercised stock options and sold shares of common stock on July 11, 2024, according to a recent SEC filing.

Shelley Thunen, CFO of RxSight, Inc., exercised stock options and sold shares on July 1, 2024, according to a Form 4 filing with the SEC.

Julie Andrews, a director at RxSight, Inc., executed sales of common stock on June 14, 2024, under a pre-arranged Rule 10b5-1 trading plan.

Director Robert Keith Warner reports acquisition of RxSight shares and restricted stock units.

Director Robert Palmisano reports acquisition of RxSight common stock and restricted stock units.

Director Shweta Maniar reported acquiring 2,554 shares of common stock and restricted stock units representing a contingent right to receive one share of RxSight, Inc. Common Stock.

Director William J. Link acquired shares and restricted stock units (RSUs) in RxSight, Inc.

Director Tamara Fountain reports acquisition of RxSight, Inc. common stock and restricted stock units (RSUs) as part of her compensation.

Director Jesse Anderson Corley reports acquiring shares and restricted stock units (RSUs) in RxSight, Inc.

Director Juliet Tammenoms Bakker reports acquisition of 2,554 shares of RxSight, Inc. common stock and ownership of 37,394 direct shares and 1,548 indirect shares.

Director Julie Andrews reports acquisition of 2,554 shares of RxSight, Inc. common stock on June 6, 2024.

Director Juliet Tammenoms Bakker purchased 5,000 shares of RxSight, Inc. at $61.0913 per share on May 17, 2024.

Ilya Goldshleger, Chief Operating Officer of RxSight, Inc., executed stock options and disposed of shares on May 17, 2024.

RxSight's CEO, Ronald M. Kurtz, sold 40,000 shares of common stock at an average price of $60.1468 per share, executed under a pre-arranged Rule 10b5-1 trading plan.

Shelley Thunen, CFO of RxSight, Inc., exercised stock options and sold shares of common stock on May 1, 2024, according to a Form 4 filing with the SEC.

Shelley Thunen, CFO of RxSight, Inc., executed multiple sales of common stock on April 1, 2024, under a pre-arranged Rule 10b5-1 trading plan.

Chief Commercial Officer Eric Weinberg of RxSight, Inc. was granted 92,200 stock options on March 4, 2024.

RxSight's Chief Operating Officer, Ilya Goldshleger, acquired 92,200 stock options on March 4, 2024, according to a Form 4 filing with the SEC.

Shelley Thunen, CFO of RxSight, Inc., reports the acquisition of 92,200 stock options on March 4, 2024.

RxSight's President and CEO, Ronald M. Kurtz, acquired 149,000 stock options on March 4, 2024, according to a Form 4 filing with the SEC.

Shelley Thunen, CFO of RxSight, Inc., exercised stock options and sold shares of common stock on March 1, 2024, under a pre-arranged Rule 10b5-1 trading plan.